BR112022021962A2 - Imidazopiridazinas como moduladores de il-17 - Google Patents

Imidazopiridazinas como moduladores de il-17

Info

Publication number
BR112022021962A2
BR112022021962A2 BR112022021962A BR112022021962A BR112022021962A2 BR 112022021962 A2 BR112022021962 A2 BR 112022021962A2 BR 112022021962 A BR112022021962 A BR 112022021962A BR 112022021962 A BR112022021962 A BR 112022021962A BR 112022021962 A2 BR112022021962 A2 BR 112022021962A2
Authority
BR
Brazil
Prior art keywords
imidazopyridazines
modulators
present
compounds
ameliorating
Prior art date
Application number
BR112022021962A
Other languages
English (en)
Portuguese (pt)
Inventor
Behenna Douglas
Deckhut Charlotte
Rovira Alexander
Goldberg Steven
Kummer David
keith John
Woods Craig
Rhorer Timothy
Tanis Virginia
Martin Connor
Meduna Steven
Mccarver Stefan
Valdes Alexander
Loskot Steven
Xue Xiaohua
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112022021962A2 publication Critical patent/BR112022021962A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)
  • Cosmetics (AREA)
  • Lubricants (AREA)
BR112022021962A 2020-04-30 2021-04-28 Imidazopiridazinas como moduladores de il-17 BR112022021962A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063017682P 2020-04-30 2020-04-30
PCT/US2021/029641 WO2021222404A1 (en) 2020-04-30 2021-04-28 Imidazopyridazines as modulators of il-17

Publications (1)

Publication Number Publication Date
BR112022021962A2 true BR112022021962A2 (pt) 2023-03-28

Family

ID=76197556

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021962A BR112022021962A2 (pt) 2020-04-30 2021-04-28 Imidazopiridazinas como moduladores de il-17

Country Status (20)

Country Link
US (3) US11691979B2 (cg-RX-API-DMAC10.html)
EP (1) EP4143195B1 (cg-RX-API-DMAC10.html)
JP (1) JP7664947B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230019507A (cg-RX-API-DMAC10.html)
CN (1) CN115884810B (cg-RX-API-DMAC10.html)
AR (1) AR121959A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021264528A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022021962A2 (cg-RX-API-DMAC10.html)
CA (1) CA3181676A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022017072A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP22091485A (cg-RX-API-DMAC10.html)
ES (1) ES3036330T3 (cg-RX-API-DMAC10.html)
IL (1) IL297705A (cg-RX-API-DMAC10.html)
JO (1) JOP20220284A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022013647A (cg-RX-API-DMAC10.html)
PE (1) PE20230469A1 (cg-RX-API-DMAC10.html)
TW (1) TWI874645B (cg-RX-API-DMAC10.html)
UY (1) UY39188A (cg-RX-API-DMAC10.html)
WO (1) WO2021222404A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202212967B (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201909190D0 (en) * 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
US12559496B2 (en) 2020-04-30 2026-02-24 Janssen Pharmaceutica Nv Imidazopyrimidines as modulators of IL-17
JP7664947B2 (ja) * 2020-04-30 2025-04-18 ヤンセン ファーマシューティカ エヌ.ベー. Il-17の調節因子としてのイミダゾリダジン
US20240140951A1 (en) * 2020-12-14 2024-05-02 UCB Biopharma SRL Imidazopyridazine derivatives as il-17 modulators
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
AU2022348938A1 (en) 2021-09-27 2024-05-16 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
AU2022349687A1 (en) 2021-09-27 2024-05-16 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
WO2023111181A1 (en) 2021-12-16 2023-06-22 Leo Pharma A/S Small molecule modulators of il-17
CN118580191A (zh) * 2022-01-28 2024-09-03 和记黄埔医药(上海)有限公司 用于制备咪唑并[1,2-b]哒嗪类化合物的中间体
EP4486737A1 (en) 2022-03-04 2025-01-08 LEO Pharma A/S Small molecule modulators of il-17
KR20250023378A (ko) * 2022-05-19 2025-02-18 다이스 알파, 인크. 락탐 치환된 이미다조피리다진 il-17a 조정제 및 그의 용도
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
CN115806503B (zh) * 2022-12-02 2025-03-07 中国海洋大学 一种选择性组蛋白去乙酰化酶抑制剂及其制备方法和应用
EP4688156A1 (en) * 2023-03-28 2026-02-11 Janssen Pharmaceutica NV Lactam-containing imidazopyridazine il-17 inhibitor compounds
WO2024215597A1 (en) * 2023-04-11 2024-10-17 Dice Alpha, Inc. Substituted 6-imidazopyridazine il-17a modulators and uses thereof
WO2025202931A1 (en) 2024-03-27 2025-10-02 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
WO2025247285A1 (zh) * 2024-05-28 2025-12-04 西藏海思科制药有限公司 一种可抑制il-17a的杂环化合物制备及其用途
WO2026080825A1 (en) * 2024-10-10 2026-04-16 Revolution Medicines, Inc. Synthesis of ras inhibitors
WO2026130488A1 (en) * 2024-12-18 2026-06-25 Anew Therapeutics Pte. Ltd. Heterocyclic compounds as il-17 inhibitors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
EP2892899B1 (en) * 2012-09-06 2018-03-21 Bristol-Myers Squibb Company Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
WO2014066726A2 (en) 2012-10-26 2014-05-01 Ensemble Therapeutics Corporation Compounds for modulating il-17
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
US10035777B2 (en) 2014-08-05 2018-07-31 Bristol-Myers Squibb Company Heterocyclic kinase inhibitors
KR102782807B1 (ko) * 2015-11-18 2025-03-14 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
GB201709456D0 (en) 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
CN111601799B (zh) * 2018-01-15 2023-06-09 Ucb生物制药有限责任公司 作为Il-17调节剂的稠合咪唑衍生物
WO2019223718A1 (zh) 2018-05-22 2019-11-28 成都先导药物开发股份有限公司 一种免疫调节剂
EP3599245A1 (en) 2018-07-27 2020-01-29 Dompé farmaceutici S.p.A. Il-17a binding polypeptides and medical uses thereof
GB201820166D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
GB201820165D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
GB201820316D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for IL-17
MX2021006421A (es) 2018-12-19 2021-08-16 Leo Pharma As Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
TWI752400B (zh) * 2019-01-07 2022-01-11 美商美國禮來大藥廠 Il-17a抑制劑
CN113874080B (zh) 2019-02-06 2024-09-27 戴斯阿尔法公司 Il-17a调节剂及其用途
EP3935051A1 (en) 2019-03-08 2022-01-12 Leo Pharma A/S Small molecule modulators of il-17
GB201909191D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909194D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
WO2021027721A1 (zh) 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341442B (zh) 2019-08-09 2021-10-22 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341439B (zh) 2019-08-09 2022-02-15 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341451B (zh) 2019-08-09 2022-06-17 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021027722A1 (zh) 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341435B (zh) 2019-08-09 2021-10-22 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021027729A1 (zh) 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341429B (zh) 2019-08-09 2021-11-23 成都先导药物开发股份有限公司 一种免疫调节剂的中间体化合物
CN112341450B (zh) 2019-08-09 2022-05-17 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021170631A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021170627A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
CN115702024A (zh) 2020-04-07 2023-02-14 Ucb生物制药有限责任公司 用作il-17调节剂的二氟环己基衍生物
WO2021204800A1 (en) 2020-04-07 2021-10-14 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
JP7664947B2 (ja) * 2020-04-30 2025-04-18 ヤンセン ファーマシューティカ エヌ.ベー. Il-17の調節因子としてのイミダゾリダジン
KR20230017211A (ko) * 2020-04-30 2023-02-03 얀센 파마슈티카 엔.브이. Il-17 경로의 조절인자를 식별하는 방법

Also Published As

Publication number Publication date
TWI874645B (zh) 2025-03-01
EP4143195A1 (en) 2023-03-08
MX2022013647A (es) 2023-02-01
CN115884810B (zh) 2025-01-17
US20220402922A1 (en) 2022-12-22
JP2023524018A (ja) 2023-06-08
US20230081548A1 (en) 2023-03-16
JOP20220284A1 (ar) 2022-10-30
ECSP22091485A (es) 2022-12-30
IL297705A (en) 2022-12-01
UY39188A (es) 2021-10-29
TW202208367A (zh) 2022-03-01
US12024524B2 (en) 2024-07-02
ES3036330T3 (en) 2025-09-17
US20230357254A1 (en) 2023-11-09
EP4143195C0 (en) 2025-05-21
CN115884810A (zh) 2023-03-31
ZA202212967B (en) 2024-06-26
PE20230469A1 (es) 2023-03-14
WO2021222404A1 (en) 2021-11-04
JP7664947B2 (ja) 2025-04-18
CA3181676A1 (en) 2021-11-04
AU2021264528A1 (en) 2023-01-19
US11702422B2 (en) 2023-07-18
KR20230019507A (ko) 2023-02-08
AR121959A1 (es) 2022-07-27
CO2022017072A2 (es) 2022-12-09
EP4143195B1 (en) 2025-05-21
US11691979B2 (en) 2023-07-04

Similar Documents

Publication Publication Date Title
ECSP22091485A (es) Imidazolpiridazinas como moduladores de il-17
BR112023016299A2 (pt) Composições e métodos para inibir kras
BR112018075465A2 (pt) agentes antivirais de hepatite b
BR112023022580A2 (pt) Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças
BR112022026321A2 (pt) Análogos de 1'-ciano nucleosídeo e usos dos mesmos
BR112018067964A2 (pt) agentes antivirais para hepatite b
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112021017604A2 (pt) Compostos úteis na terapia para hiv
BR112014023384A2 (pt) inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112013020620A2 (pt) análogos de ácido 4-hidroxibutírico
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
BR112013029240A2 (pt) derivados deuterados do ivacaftor
BR112015018751A2 (pt) derivados de piridazinona macrocíclicos
BR112017020837A2 (pt) compostos de carbamoilpiridona policíclicos e seu uso farmacêutico
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112022021957A2 (pt) Imidazopirimidinas como moduladores de il -17
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
BRPI0912294B8 (pt) compostos de triazina que inibem p13 quinase e mtor, e composições farmacêuticas dos mesmos
BR112014008686A2 (pt) derivados de oxazina e uso dos mesmos no tratamento de doença
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
CO2024003723A2 (es) Compuestos de imidazopiridazina inhibidores de il-17
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112017009647A2 (pt) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements